Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Nurix Therapeutics, Inc.

NASDAQ: NRIX · Life Sciences · 11 alerts · CIK 1549595

Share price
$14.73Close, Nov 16
Market cap
$1.61B
Shares outstanding
109.25MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nurix Therapeutics, Inc. filings on SEC EDGAR ↗

4:02 PM ET 8-K
Deal Termination

Nurix Therapeutics Deal Termination with Sanofi S.A.

Nurix Therapeutics announced that its collaboration partner Sanofi has decided to discontinue the Phase 1 clinical trial and terminate the SAR448272 oral STAT6 degrader program. As a result, Nurix will no longer be eligible for future development, regulatory, or commercial milestone payments and royalties specifically for this program, though other licensed programs under the Sanofi collaboration remain active.

Counterparty
Sanofi S.A.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.